CAS NO: | 380610-27-5 |
包装 | 价格(元) |
1mg | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
生物活性 | Pertuzumab, a humanizedIgG1monoclonal antibody, is aHER2dimerization inhibitor for the treatment of metastatic HER2-positive breastcancer. | |
IC50& Target |
| |
体外研究 (In Vitro) | Trastuzumab and Pertuzumab are highly synergistic inhibitors of BT474 breast cancer cell survival. The combination of trastuzumab and Pertuzumab mediates a loss of up to 60% of cells at doses in which individual drugs do not alter cell survival. The combination of trastuzumab and Pertuzumab reduces the percentage of proliferating (S-phase) cells by more than 2-fold. A combination of trastuzumab and Pertuzumab inhibits cell proliferation and survival to a greater degree than does either agent alone[1]. | |
体内研究 (In Vivo) | In Calu-3 NSCLC xenografts, monotherapy with pertuzumab or trastuzumab is able to significantly inhibit tumor growth, with treatment-to-control ratios (TCR) of 0.23 and 0.27, respectively. The combination of trastuzumab and pertuzumab produces a dramatically enhanced antitumor activity compared with single-agent treatments (TCR 0.05, resulting in tumor regression and, in 3 of 10 animals, complete tumor remission). Treatment of KPL-4 breast cancer xenografts with either trastuzumab or pertuzumab inhibits tumor growth with TCRs of 0.67 and 0.65, respectively. Pertuzumab maintains antitumor activity after progression on trastuzumab[2]. | |
Clinical Trial | ||
分子量 | 145175.18 | |
性状 | Liquid | |
CAS 号 | 380610-27-5 | |
中文名称 | 帕妥株单抗 | |
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |